Phase 2Status unknown
Study Exploring the Supportive Effect of Acarbose in Weight Management
A 26-week, Double-blind, Randomized Study in Participants With Overweight or Obesity Investigating the Added Contribution of Acarbose in EMP16 on Efficacy, Safety and Tolerability
- Sponsor
- Empros Pharma AB (Industry)
- Enrollment
- 320 planned
- Conditions
- Overweight or Obesity
- Interventions
- EMP16-120/40; MR orlistat 120 mg; Conventional orlistat 120 mg,; EMP16-60/20; Placebo
- Ages
- adults, older adults
- Registry
- NCT05934110, EUCTR2022-003320-40
Full record on ClinicalTrials.gov
From the registry
This is a randomized, double-blind study in participants with overweight or obesity in which the effect of acarbose and the impact of dose on efficacy, safety and tolerability is investigated by comparing the EMP16 combination product with modified release (MR) orlistat, orlistat in its conventional dosage form and placebo.
Primary outcomes
- Relative (%) change from baseline in body weight at week 26
- Proportion of participants with ≥5% decrease in body weight at week 26 [Please note: This is an FDA required outcome, cannot use "change"]
History
Study completion
Last registry update
Primary completion
Registered
Started